|
|
|
| Research progress of SGLT-2 inhibitors in the treatment of diabetic nephropathy |
| XU Qi FU Jia HAN Rui |
| The Second Department of Endocrinology, the First Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650032, China |
|
|
|
Abstract Sodium-glucose transporter-2 (SGLT-2) is upregulated in patients with diabetes, and it is responsible for approximately 90% of the reabsorption of urine glucose in the proximal tubules. SGLT-2 inhibitor is a new type of hypoglycemic agent which can reduce the expression of hypoxia-inducible factor-1 protein and kidney injury molecule-1, and improve the activation of the renin-angiotensin-aldosterone system, while reduce the generation of oxidative stress. It can also protect the kidneys by reducing blood sugar, blood pressure, uric acid and improving lipid metabolism. In addition, SGLT-2 inhibitors combined with angiotensin-converting enzyme inhibitor are used to treat patients with type 2 diabetes combined with chronic kidney disease. SGLT-2 inhibitors have good safety in patients with diabetic nephropathy, but we need to pay attention to the increased risk of urinary tract infections of Dapagliflozin, and at the same time be alert to the risk of acute kidney injury of Canagliflozin and Dapagliflozin. This article reviews the effects of SGLT-2 inhibitors on the kidney and its clinical application in the treatment of diabetic nephropathy in order to provide new treatment options for diabetic nephropathy.
|
|
|
|
|
|
[1] Saran R，Robinson B，Abbott KC，et al. US Renal Data System 2018 Annual Data Report：Epidemiology of Kidney Disease in the United States [J]. Am J Kidney Dis，2019， 73（3S1）：A7-A8.
[2] Ghezzi C，Loo DDF，Wright EM. Physiology of renal glucose handling via SGLT1，SGLT2 and GLUT2 [J]. Diabetologia，2018，61（10）：2087-2097.
[3] Mishra R，Emancipator SN，Kern T，et al. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells [J]. Kidney Int，2005，67（1）：82-93.
[4] Bessho R，Takiyama Y，Takiyama T，et al. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy [J]. Sci Rep，2019，9（1）：14754.
[5] Kamezaki M，Kusaba T，Komaki K，et al. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice [J]. Sci Rep，2018，8（1）：4029.
[6] Sasaki T，Seino Y，Fukatsu A，et al. Pharmacokinetics，Pharmacodynamics，and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus：A Randomized，Single-blind，Placebo-controlled Trial [J]. Adv Ther，2015， 32（4）：319-340.
[7] Visavadiya NP，Li Y，Wang S. High Glucose Upregulates Upstream Stimulatory Factor 2 in Human Renal Proximal Tubular Cells through Angiotensin Ⅱ-Dependent Activation of CREB [J]. Nephron Exp Nephrol，2011，117（3）：e62-e70.
[8] Shin SJ，Chung S，Kim SJ，et al. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor，Dapagliflozin，on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes [J]. PLoS One，2016，11（11）：e0165703.
[9] Takiyama Y，Sera T，Nakamura M，et al. Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice，as Estimated by Synchrotron Radiation Micro-CT at SPring-8 [J]. E Bio Medicine，2018，36：329-346.
[10] Gallo LA，Ward MS，Fotheringham AK，et al. Once daily administration of the SGLT2 inhibitor，empagliflozin，attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice [J]. Sci Rep，2016，6：26428.
[11] Jia Y，He J，Wang L，et al. Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice [J]. Cell Physiol Biochem，2018，45（5）：1747-1758.
[12] Nishimura R，Osonoi T，Kanada S，et al. Effects of luse-ogliflozin，a sodium-glucose co-transporter 2 inhibitor，on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus：a randomized，double-blind，placebo-controlled，crossover study [J]. Diabetes Obes Metab，2015，17（8）：800-804.
[13] Sahasrabudhe V，Terra SG，Hickman A，et al. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects with Type 2 Diabetes Mellitus [J]. J Clin Pharmacol，2017，57（11）：1432-1443.
[14] Seino Y，Yabe D，Sasaki T，et al. SGLT2 inhibitor luseog-liflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes：a 52-week，open-label，single-arm study [J]. J Diabetes Investig，2018，9（2）：332-340.
[15] Pessoa TD，Campos LC，Carraro-Lacroix L，et al. Functional Role of Glucose Metabolism，Osmotic Stress，and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule [J]. J Am Soc Nephrol，2014，25（9）：2028-2039.
[16] Kawasoe S，Maruguchi Y，Kajiya S，et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes [J]. BMC Pharmacol Toxicol，2017，18（1）：23.
[17] Chino Y，Samukawa Y，Sakai S，et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria [J]. Biopharm Drug Dispos，2014，35（7）：391-404.
[18] Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes：a secondary analysis of the Look AHEAD randomised clinical trial [J]. Lancet Diabetes Endocrinol，2014，2（10）：801-809.
[19] Xu L，Nagata N，Nagashimada M，et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice [J]. EBioMedicine，2017，20：137-149.
[20] Tosaki T，Kamiya H，Himeno T，et al. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes [J]. Intern Med，2017，56（6）：597-604.
[21] Storgaard H，Gluud LL，Bennett C，et al. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes：A Systematic Review and Meta-Analysis [J]. PLoS One，2016，11（11）：e0166125.
[22] Grunberger G，Camp S，Johnson J，et al. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus：The VERTIS RENAL Randomized Study [J]. Diabetes Ther，2018，9（1）：49-66.
[23] Kashiwagi A，Takahashi H，Ishikawa H，et al. A randomized，double-blind，placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment：results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment（LANTERN）study [J]. Diabetes Obes Metab，2015，17（2）：152-160.
[24] Ito D，Inoue K，Sumita T，et al. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes：104-Week Follow-up of an Open-Label Study [J]. J Clin Med Res，2018， 10（9）：679-687.
[25] Kojima N，Williams JM，Takahashi T，et al. Effects of a New SGLT2 Inhibitor，Luseogliflozin，on Diabetic Nephr-opathy in T2DN Rats [J]. J Pharmacol Exp Ther，2013， 345（3）：464-472.
[26] 隋超，陈亚镇，赖贻旺.血管紧张素转化酶抑制剂联合SGLT-2抑制剂治疗糖尿病肾病效果研究[J].临床军医杂志，2018，46（12）：1437-1438，1440.
[27] Yeo SM，Park H，Paek JH，et al. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin：A case report [J]. Medicine（Baltimore），2019，98（3）：e14150.
[28] Donnan JR，Grandy CA，Chibrikov E，et al. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections：a systematic review and network meta-analysis of randomized controlled trials [J]. CMAJ Open，2018，6（4）：E594-E602.
[29] Puckrin R，Saltiel MP，Reynier P，et al. SGLT-2 inhibitors and the risk of infections：a systematic review and meta-analysis of randomized controlled trials [J]. Acta Diabetol，2018，55（5）：503-514.
[30] The U.S. Food and drug administration. FDA Drug Safety Communication：FDA strengthens kidney warnings for diabetes medicines canagliflozin（Invokana，Invokamet）and dapagliflozin（Farxiga，Xigduo XR）[EB/OL].（2016-06-17）https：//www.fda.gov/media/98683/download |
|
|
|
